Lund, May 19th, 2014
For release 3:00 p.m. CET, 9:00 a.m. EST, May 19th, 2014
Merck Serono selects TFS as a Preferred Provider for Phase IV Studies in Western Europe and North America
On March 14th, 2014, Merck Serono, a division of Merck KGaA, Darmstadt, Germany and TFS International, signed a three-year Agreement to support Merck Serono clinical operations in regional/local Phase IV Studies in Western Europe and North America.
Under this Agreement TFS will provide clinical service capabilities to support Merck Serono’s portfolio in Phase IV Studies. TFS’ selection as one of the Preferred Providers for Western Europe and North America was based, in part, on the company’s “exceptional way of doing business in the local regions” and “having the cultural connectivity with local markets”.
A main objective in Merck Serono´s outsourcing model is to define a harmonized, cost effective outsourcing strategy by consolidating the number of preferred providers while enabling the implementation of the same level of standards across the globe. This strategy will enable Merck Serono to leverage operational synergies. The process began by defining the geographical regions and number of providers, respectively. The selected group of CROs was whittled down to a cohort of eight worldwide, based upon an innovative operating model and performance of the providers in the selected regions.
TFS will work as a close preferred provider to Merck Serono in implementing the Western European and North American clinical outsourcing model which will drive functional excellence, capture synergies, introduce standardized process and improve efficiency.
Financial forecasts are not announced by the parties.
For further information please contact:
Ms. Gordana Clavères
Marketing and Communications Assoc.